Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 2/20 | 0.46 |
| ▸ | MTTP | P55157 | 2/20 | 0.44 |
| ▸ | APOB | P04114 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 3/20 | 0.43 |
| ▸ | HTR2C | P28335 | 3/20 | 0.43 |
| ▸ | HTR2B | P41595 | 3/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 6/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489620 | 0.88 | ABCB1 (0.51) | ABCB1ABCG2 | |
| SCHEMBL6498905 | 0.88 | ABCB1 (0.42) | SMOMTTPAPOBABCB1ABCG2 | |
| SCHEMBL6496773 | 0.88 | ABCB1 (0.40) | SMOMTTPAPOBABCB1ABCG2 | |
| SCHEMBL8201197 | 0.87 | SMO (0.63) | SMOMTTPAPOBHTR2AHTR2C | |
| SCHEMBL6503264 | 0.84 | HTR1A (0.51) | TRPV1 | |
| SCHEMBL6487457 | 0.84 | DRD2 (0.47) | SMOMTTPAPOBABCB1ABCG2 | |
| SCHEMBL6501026 | 0.84 | SMO (0.46) | SMOMTTPAPOBHTR2AHTR2C | |
| SCHEMBL6491779 | 0.81 | ACACB (0.43) | MTTPAPOB | |
| SCHEMBL6487662 | 0.81 | TRPV1 (0.49) | SMOMTTPAPOBTRPV1NAMPT | |
| SCHEMBL6489031 | 0.80 | HTR2A (0.51) | SMOMTTPAPOBHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
| EP-1472226-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003045921-A1 | HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | SMO 2580/4885MTTP 677/4885APOB 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.